Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Rituximab 24Cyclophosphamide 14fludarabine 8Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5fludarabine phosphate 4Carboplatin 4venetoclax 3obinutuzumab 3ibrutinib 3atezolizumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Cytarabine 3Carmustine 3Bortezomib 3Bendamustine Hydrochloride 3ublituximab 2pembrolizumab 2pegfilgrastim 2ibritumomab tiuxetan 2Tiragolumab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Indium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell × sepantronium × Clear all
NCT00498914 2015-09-04

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Astellas Pharma Inc

Phase 2 Terminated
41 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡